Effect and the probable mechanisms of silibinin in regulating insulin resistance in the liver of rats with non-alcoholic fatty liver

Brazilian Journal of Medical and Biological Research

Volumn 46, Issue 3, 2013, Pages 270-277

  Yao, Jiayin ^a   Zhi, Min ^a   Gao, Xiang ^a   Hu, Pinjin ^a   Li, Chujun ^a   Yang, Xiaobo ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Insulin resistance; Non alcoholic fatty liver disease; Silibinin; Visceral obesity

Indexed keywords

GLUCOSE 6 PHOSPHATASE; HEPATOCYTE NUCLEAR FACTOR 3ALPHA; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP); SILIBININ; TRIACYLGLYCEROL LIPASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTOPSY; BODY FAT DISTRIBUTION; CONTROLLED STUDY; DRUG EFFECT; GLUCONEOGENESIS; GLUCOSE TOLERANCE TEST; HOMEOSTASIS AND REGULATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN TOLERANCE TEST; LIPID DIET; LIPOLYSIS; LIVER FUNCTION; LIVER HISTOLOGY; MALE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUBCUTANEOUS FAT;

EID: 84876471326     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/1414-431X20122551     Document Type: Article

References (40)

1. Argo CK, Caldwell SH. Epidemiology and natural history of non-alcoholic steatohepatitis. Clin Liver Dis 2009; 13: 511-531, doi: 10.1016/j.cld.2009.07.005.
2. Amarapurkar DN, Hashimoto E, Lesmana LA, Sollano JD, Chen PJ, Goh KL. How common is non-alcoholic fatty liver disease in the Asia-Pacific region and are there local differences? J Gastroenterol Hepatol 2007; 22: 788-793, doi: 10.1111/j.1440-1746.2007.05042.x.
3. de Silva HJ, Dassanayake AS. Non-alcoholic fatty liver disease: confronting the global epidemic requires better awareness. J Gastroenterol Hepatol 2009; 24: 1705-1707, doi: 10.1111/j.1440-1746.2009.06026.x.
4. Loguercio C, Festi D. Silybin and the liver: from basic research to clinical practice. World J Gastroenterol 2011; 17: 2288-2301, doi: 10.3748/wjg.v17.i18.2288.
5. Trappoliere M, Federico A, Tuccillo C, de Sio I, Di Leva A, Niosi M, et al. [Effects of a new pharmacological complex (silybin + vitamin-E + phospholipids) on some markers of the metabolic syndrome and of liver fibrosis in patients with hepatic steatosis. Preliminary study]. Minerva Gastroenterol Dietol 2005; 51: 193-199.
6. Federico A, Trappoliere M, Tuccillo C, de Sio I, Di Leva A, Del Vecchio Blanco C, et al. A new silybin-vitamin Ephospholipid complex improves insulin resistance and liver damage in patients with non-alcoholic fatty liver disease: preliminary observations. Gut 2006; 55: 901-902, doi: 10.1136/gut.2006.091967.
7. Yao J, Zhi M, Minhu C. Effect of silybin on high-fat-induced fatty liver in rats. Braz J Med Biol Res 2011; 44: 652-659.
8. Hallsworth K, Fattakhova G, Hollingsworth KG, Thoma C, Moore S, Taylor R, et al. Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss. Gut 2011; 60: 1278-1283, doi: 10.1136/gut.2011.242073.
9. Jacobs M, van Greevenbroek MM, van der Kallen CJ, Ferreira I, Feskens EJ, Jansen EH, et al. The association between the metabolic syndrome and alanine amino transferase is mediated by insulin resistance via related metabolic intermediates (the Cohort on Diabetes and Atherosclerosis Maastricht [CODAM] study). Metabolism 2011; 60: 969-975, doi: 10.1016/j.metabol.2010.09.006.
10. Pagel-Langenickel I, Bao J, Pang L, Sack MN. The role of mitochondria in the pathophysiology of skeletal muscle insulin resistance. Endocr Rev 2010; 31: 25-51, doi: 10.1210/er.2009-0003.
11. Perseghin G, Calori G, Lattuada G, Ragogna F, Dugnani E, Garancini MP, et al. Insulin resistance/hyperinsulinemia and cancer mortality: the Cremona study at the 15th year of follow-up. Acta Diabetol 2012; 49: 421-428, doi: 10.1007/ s00592-011-0361-2.
12. Zelber-Sagi S, Lotan R, Shlomai A, Webb M, Harrari G, Buch A, et al. Predictors for incidence and remission of NAFLD in the general population during a seven-year prospective follow-up. J Hepatol 2012; 56: 1145-1151, doi: 10.1016/j.jhep.2011.12.011.
13. Svegliati-Baroni G, Bugianesi E, Bouserhal T, Marini F, Ridolfi F, Tarsetti F, et al. Post-load insulin resistance is an independent predictor of hepatic fibrosis in virus C chronic hepatitis and in non-alcoholic fatty liver disease. Gut 2007; 56: 1296-1301, doi: 10.1136/gut.2006.107946.
14. Leclercq IA, Da Silva Morais A, Schroyen B, Van Hul N, Geerts A. Insulin resistance in hepatocytes and sinusoidal liver cells: mechanisms and consequences. J Hepatol 2007; 47: 142-156, doi: 10.1016/j.jhep.2007.04.002.
15. Korsic M, Fister K, Ivankovic D, Jelcic J. [Visceral obesity]. Lijec Vjesn 2011; 133: 284-287.
16. Smith BW, Adams LA. Non-alcoholic fatty liver disease. Crit Rev Clin Lab Sci 2011; 48: 97-113, doi: 10.3109/ 10408363.2011.596521.
17. Mollica MP, Lionetti L, Moreno M, Lombardi A, De Lange P, Antonelli A, et al. 3,5-Diiodo-L-thyronine, by modulating mitochondrial functions, reverses hepatic fat accumulation in rats fed a high-fat diet. J Hepatol 2009; 51: 363-370, doi: 10.1016/j.jhep.2009.03.023.
18. Qi C. Chinese traditional medicine pharmacological research methodology. Guangzhou: People's Medical Publishing Company; 2006.
19. Yong J, Rasooly J, Dang H, Lu Y, Middleton B, Zhang Z, et al. Multimodality imaging of beta-cells in mouse models of type 1 and 2 diabetes. Diabetes 2011; 60: 1383-1392, doi: 10.2337/db10-0907.
20. Fan R, Kang Z, He L, Chan J, Xu G. Exendin-4 improves blood glucose control in both young and aging normal nondiabetic mice, possible contribution of beta cell independent effects. PLoS One 2011; 6: e20443, doi: 10.1371/journal.-pone.0020443.
21. Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani F, Zenere MB, et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000; 23: 57-63, doi: 10.2337/diacare. 23.1.57.
22. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-1321, doi: 10.1002/hep.20701.
23. Kuwashiro S, Terai S, Oishi T, Fujisawa K, Matsumoto T, Nishina H, et al. Telmisartan improves nonalcoholic steatohepatitis in medaka (Oryzias latipes) by reducing macrophage infiltration and fat accumulation. Cell Tissue Res 2011; 344: 125-134, doi: 10.1007/s00441-011-1132-7.
24. Hjelkrem M, Stauch C, Shaw J, Harrison SA. Validation of the non-alcoholic fatty liver disease activity score. Aliment Pharmacol Ther 2011; 34: 214-218, doi: 10.1111/j.1365-2036.2011.04695.x.
25. Burcelin R, Crivelli V, Dacosta A, Roy-Tirelli A, Thorens B. Heterogeneous metabolic adaptation of C57BL/6J mice to high-fat diet. Am J Physiol Endocrinol Metab 2002; 282: E834-E842.
26. Bolum T, Kolaric B, Duvnjak L, Duvnjak M. Nonalcoholic fatty liver disease markers are associated with insulin resistance in type 1 diabetes. Dig Dis Sci 2011; 56: 3655-3663, doi: 10.1007/s10620-011-1807-7.
27. Feng B, Jiao P, Nie Y, Kim T, Jun D, van Rooijen N, et al. Clodronate liposomes improve metabolic profile and reduce visceral adipose macrophage content in diet-induced obese mice. PLoS One 2011; 6: e24358, doi: 10.1371/journal.-pone.0024358.
28. Votruba SB, Jensen MD. Insulin sensitivity and regional fat gain in response to overfeeding. Obesity 2011; 19: 269-275, doi: 10.1038/oby.2010.274.
29. Riserus U, Arnlov J, Brismar K, Zethelius B, Berglund L, Vessby B. Sagittal abdominal diameter is a strong anthropometric marker of insulin resistance and hyperproinsulinemia in obese men. Diabetes Care 2004; 27: 2041-2046, doi: 10.2337/diacare.27.8.2041.
30. Pietilainen KH, Naukkarinen J, Rissanen A, Saharinen J, Ellonen P, Keranen H, et al. Global transcript profiles of fat in monozygotic twins discordant for BMI: pathways behind acquired obesity. PLoS Med 2008; 5: e51, doi: 10.1371/ journal.pmed.0050051.
31. Samuel VT, Liu ZX, Qu X, Elder BD, Bilz S, Befroy D, et al. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem 2004; 279: 32345-32353, doi: 10.1074/jbc.M313478200.
32. Etschmaier K, Becker T, Eichmann TO, Schweinzer C, Scholler M, Tam-Amersdorfer C, et al. Adipose triglyceride lipase affects triacylglycerol metabolism at brain barriers. J Neurochem 2011; 119: 1016-1028, doi: 10.1111/j.1471-4159.2011.07498.x.
33. Huijsman E, van de Par C, Economou C, van der Poel C, Lynch GS, Schoiswohl G, et al. Adipose triacylglycerol lipase deletion alters whole body energy metabolism and impairs exercise performance in mice. Am J Physiol Endocrinol Metab 2009; 297: E505-E513, doi: 10.1152/ ajpendo.00190.2009.
34. Zechner R, Kienesberger PC, Haemmerle G, Zimmermann R, Lass A. Adipose triglyceride lipase and the lipolytic catabolism of cellular fat stores. J Lipid Res 2009; 50: 3-21, doi: 10.1194/jlr.R800031-JLR200.
35. Lee HY, Birkenfeld AL, Jornayvaz FR, Jurczak MJ, Kanda S, Popov V, et al. Apolipoprotein CIII overexpressing mice are predisposed to diet-induced hepatic steatosis and hepatic insulin resistance. Hepatology 2011; 54: 1650-1660, doi: 10.1002/hep.24571.
36. Kim SP, Ellmerer M, Van Citters GW, Bergman RN. Primacy of hepatic insulin resistance in the development of the metabolic syndrome induced by an isocaloric moderate-fat diet in the dog. Diabetes 2003; 52: 2453-2460, doi: 10.2337/diabetes.52.10.2453.
37. Cao R, Cronk ZX, Zha W, Sun L, Wang X, Fang Y, et al. Bile acids regulate hepatic gluconeogenic genes and farnesoid X receptor via G(alpha)i-protein-coupled receptors and the AKT pathway. J Lipid Res 2010; 51: 2234-2244, doi: 10.1194/jlr.M004929.
38. Kabir M, Catalano KJ, Ananthnarayan S, Kim SP, Van Citters GW, Dea MK, et al. Molecular evidence supporting the portal theory: a causative link between visceral adiposity and hepatic insulin resistance. Am J Physiol Endocrinol Metab 2005; 288: E454-E461, doi: 10.1152/ ajpendo.00203.2004.
39. Nagashima T, Shigematsu N, Maruki R, Urano Y, Tanaka H, Shimaya A, et al. Discovery of novel forkhead box O1 inhibitors for treating type 2 diabetes: improvement of fasting glycemia in diabetic db/db mice. Mol Pharmacol 2010; 78: 961-970, doi: 10.1124/mol.110.065714.
40. Qu S, Altomonte J, Perdomo G, He J, Fan Y, Kamagate A, et al. Aberrant Forkhead box O1 function is associated with impaired hepatic metabolism. Endocrinology 2006; 147: 5641-5652, doi: 10.1210/en.2006-0541.